Sino Biopharmaceutical Limited
SBMFF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $28,866,159 | $26,199,409 | $26,026,164 | $26,861,356 |
| % Growth | 10.2% | 0.7% | -3.1% | – |
| Cost of Goods Sold | $5,336,218 | $4,989,877 | $5,795,510 | $5,332,095 |
| Gross Profit | $23,529,941 | $21,209,532 | $21,538,548 | $21,529,261 |
| % Margin | 81.5% | 81% | 82.8% | 80.1% |
| R&D Expenses | $5,234,903 | $4,473,018 | $4,332,600 | $3,747,078 |
| G&A Expenses | $2,081,510 | $1,873,284 | $2,204,697 | $2,185,234 |
| SG&A Expenses | $12,159,476 | $11,066,635 | $12,564,007 | $12,703,627 |
| Sales & Mktg Exp. | $10,077,966 | $9,193,351 | $9,809,372 | $10,518,393 |
| Other Operating Expenses | $0 | $0 | -$943,883 | $735,117 |
| Operating Expenses | $17,394,379 | $15,539,653 | $15,952,724 | $17,185,822 |
| Operating Income | $6,135,562 | $5,785,714 | $5,585,824 | $5,078,556 |
| % Margin | 21.3% | 22.1% | 21.5% | 18.9% |
| Other Income/Exp. Net | -$858,094 | -$375,808 | -$370,955 | $13,494,117 |
| Pre-Tax Income | $5,277,468 | $5,409,906 | $5,214,869 | $18,572,673 |
| Tax Expense | $492,918 | $797,267 | $696,716 | $1,957,880 |
| Net Income | $3,499,834 | $2,331,939 | $2,543,570 | $14,608,412 |
| % Margin | 12.1% | 8.9% | 9.8% | 54.4% |
| EPS | 0.2 | 0.079 | 0.11 | 0.78 |
| % Growth | 153.2% | -28.2% | -85.9% | – |
| EPS Diluted | 0.19 | 0.1 | 0.12 | 0.73 |
| Weighted Avg Shares Out | 17,244,444 | 23,391,905 | 18,622,249 | 18,768,650 |
| Weighted Avg Shares Out Dil | 18,295,060 | 18,529,065 | 19,017,202 | 19,282,955 |
| Supplemental Information | – | – | – | – |
| Interest Income | $499,564 | $186,675 | $195,908 | $162,057 |
| Interest Expense | $295,117 | $495,237 | $429,494 | $308,617 |
| Depreciation & Amortization | $939,853 | $1,074,284 | $1,046,984 | $992,556 |
| EBITDA | $6,108,662 | $6,979,427 | $6,691,347 | $19,873,846 |
| % Margin | 21.2% | 26.6% | 25.7% | 74% |